Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

By
Justin.choi
-
0
28
Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for cytokine release syndrome, which is a common cause of adverse clinical outcomes in COVID-19.
[Trends in Pharmacological Sciences]
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020). Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends in Pharmacological Sciences, 0(0). https://doi.org/10.1016/j.tips.2020.06.007 Cite
Full Article